Journal
NATURE GENETICS
Volume 43, Issue 9, Pages 879-U90Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ng.893
Keywords
-
Categories
Funding
- Cancer Research UK [C8620/A8372, C8620/A8857, C12292/A11174]
- US Military Acquisition (ACQ) Activity
- Era of Hope Award [W81XWH-05-1-0204]
- Breakthrough Breast Cancer
- Institute of Cancer Research (UK)
- NHS
- Medical Research Council (MRC) [G0000934]
- Wellcome Trust [068545/Z/02]
- MRC [G0000934, G0700491] Funding Source: UKRI
- Cancer Research UK [11174] Funding Source: researchfish
- Medical Research Council [G0000934, G0700491] Funding Source: researchfish
Ask authors/readers for more resources
Recently, RAD51C mutations were identified in families with breast and ovarian cancer(1). This observation prompted us to investigate the role of RAD51D in cancer susceptibility. We identified eight inactivating RAD51D mutations in unrelated individuals from 911 breast-ovarian cancer families compared with one inactivating mutation identified in 1,060 controls (P = 0.01). The association found here was principally with ovarian cancer, with three mutations identified in the 59 pedigrees with three or more individuals with ovarian cancer (P = 0.0005). The relative risk of ovarian cancer for RAD51D mutation carriers was estimated to be 6.30 (95% CI 2.86-13.85, P = 4.8 x 10(-6)). By contrast, we estimated the relative risk of breast cancer to be 1.32 (95% CI 0.59-2.96, P = 0.50). These data indicate that RAD51D mutation testing may have clinical utility in individuals with ovarian cancer and their families. Moreover, we show that cells deficient in RAD51D are sensitive to treatment with a PARP inhibitor, suggesting a possible therapeutic approach for cancers arising in RAD51D mutation carriers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available